Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:34:07.036Z.
Calculation as of: 2026-10-06T17:34:07.036Z.
Quote observation: 2026-10-06T17:27:57.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a4f1da35868143a3e9cc9e15baeeae426ebbcf8636af82277700bcf7ee6cbb8a
PE RATIO
N/A
Market Cap
$78.31M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sera Prognostics, Inc. (SERA) | $77.53M | N/A | N/A | N/A | N/A |
| Pulmonx Corporation (LUNG)vs › | $77.08M | N/A | N/A | N/A | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.07M | N/A | N/A | N/A | N/A |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $78.31M | N/A | N/A | N/A | N/A |
| SkinHealth Systems Inc. (SKIN)vs › | $76.37M | N/A | 63.47 | 35.79 | 35.79 |
| Hyperfine, Inc. (HYPR)vs › | $76.64M | N/A | N/A | N/A | N/A |
| Outset Medical, Inc. (OM)vs › | $75.35M | N/A | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $79.96M | N/A | N/A | N/A | N/A |
| Nutriband Inc. (NTRB)vs › | $80.11M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $80.90M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$2.03
Forward EPS (Est.)
$-0.66
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
